Claimed effect · Pramlintide

Does Pramlintide help with body weight?

B
Grade B — probable, not settled1 RCT (n=411) with 8-month extension · effect size: moderate
Short answerProbable, not settled. Human data exist (1 RCT (n=411) with 8-month extension) and mostly agree, showing a moderate effect — but too few, too small, or not yet peer-reviewed for a firm answer. Three-times-daily and higher twice-daily doses produced 3 kg more loss than placebo at four months and 6–7 kg at twelve, with placebo regaining and pramlintide maintaining. Never pursued to approval for obesity.

What the studies show

Three-times-daily and higher twice-daily doses produced 3 kg more loss than placebo at four months and 6–7 kg at twelve, with placebo regaining and pramlintide maintaining. Never pursued to approval for obesity.

“Placebo-corrected weight loss with 120 microg t.i.d. and 360 microg b.i.d. averaged 3.2 +/- 1.2 kg (3.1 +/- 1.1% body wt) and 3.3 +/- 1.1 kg (3.1 +/- 1.0% body wt), respectively, at month 4 (both P < 0.01; 4-month evaluable n = 270) and 6.1 +/- 2.1 kg (5.6 +/- 2.1% body wt) and 7.2 +/- 2.3 kg (6.8 +/- 2.3% body wt), respectively, at month 12 (both P < 0.01; 12-month evaluable n = 146).”

Verbatim, from the abstractSmith SR, Aronne LJ, Burns CM, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care, 2008

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1

In context

Pramlintide is a synthetic analogue of amylin, the hormone the pancreas releases with insulin to slow digestion and signal fullness. It is approved in the United States — and nowhere else — as an injection taken with meals alongside insulin in type 1 and type 2 diabetes. In people with obesity but no diabetes, a 12-month trial produced about 6–7 kg of placebo-corrected weight loss at the best doses, with nausea in up to a third at the start. It was never a commercial success, but its mechanism is the one cagrilintide and amycretin have since made weekly.

Pramlintide is approved (rx, us only). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Pramlintide proven to help with body weight?
Not yet settled. 1 RCT (n=411) with 8-month extension — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
Three-times-daily and higher twice-daily doses produced 3 kg more loss than placebo at four months and 6–7 kg at twelve, with placebo regaining and pramlintide maintaining. Never pursued to approval for obesity.
Is Pramlintide approved for this?
Pramlintide is an approved medicine (Approved (Rx, US only)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Pramlintide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →